ATEA PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2021 - Q4(Oct 21 · Nov 21 · Dec 21)
Total Assets
$315M
↓-32.2% -$149Mvs FY2024
Total Liabilities
$40M
↑+113.9% +$21Mvs FY2024
Equity
$275M
↓-37.2% -$163Mvs FY2024
Cash
$96M
↑+47.9% +$31Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $315M | $465M |
| Current Assets | $311M | $462M |
| Cash | $96M | $65M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $215M | $398M |
| Non-Current Assets | $4M | $2M |
| PPE | $457K | $873K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $4M | $1M |
| Total Liab+Eq | $315M | $465M |
| Current Liab. | $40M | $19M |
| Accounts Payable | $13M | $4M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $27M | $14M |
| Non-Current Liab. | $0 | $7M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $0 | $7M |
| Equity | $275M | $439M |
| Retained Earnings | $523M | $364M |
| Other Equity | $0 | $75M |
QuarterCharts · SEC EDGAR data · AVIR · Comparing FY2025 vs FY2024